Abstract
Alnylam Pharmaceuticals and PeptiDream are partnering to develop a peptide-based delivery system for Alnylam’s small interfering RNA (siRNA) therapies that silence gene expression. Alnylam has three commercial siRNA drugs that target genes in the liver, but delivering siRNA to other organs has proved challenging. PeptiDream will design peptides to create peptide-siRNA conjugates that target cell receptors outside the liver. Alnylam will pay PeptiDream an undisclosed up-front payment, R&D costs, and milestone payments up to $2.2 billion.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
